{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    4,
    30,
    31,
    40,
    46,
    51,
    53,
    54
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 0.8,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_4",
        "affectedSection": "Section 1.3.3.2 - Study GS-US-426-3988",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated preliminary safety and pharmacokinetic data for GS-0976 in subjects with hepatic impairment."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_4",
        "affectedSection": "Section 1.4.3.2 - Study GS-US-402-3885",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated subject disposition and enrollment status for GS-9674 hepatic impairment study."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_4",
        "affectedSection": "Section 1.6.2 - Rationale for Dose Selection of GS-0976",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Refined dose rationale based on updated exposure margins and NOAEL data from nonclinical studies."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_4",
        "reasonText": "Incorporation of emerging clinical and nonclinical data to support the safety and dosing rationale of the investigational products in subjects with advanced fibrosis and cirrhosis.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_4",
        "reasonText": "Update on the status of ongoing Phase 1 and Phase 2 studies (GS-US-426-3988 and GS-US-402-3885).",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_4",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.3.3.2.2",
        "beforeText": "Not explicitly provided in snippet",
        "afterText": "In the mild hepatic impairment cohort, 1 subject (10%) had a treatment-related AE of facial flushing... In the moderate hepatic impairment cohort, 3 subjects had Grade 3 lab abnormalities.",
        "summary": "Updated preliminary safety results for GS-0976 in hepatic impairment cohorts."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_4",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.6.2",
        "beforeText": "Not explicitly provided in snippet",
        "afterText": "GS-0976 exposures in subjects with mild hepatic impairment (CP A) are expected to remain ≥22 and ≥105-fold lower than the GS-0976 exposures observed at the NOAELs.",
        "summary": "Updated exposure margin calculations relative to NOAEL for GS-0976 based on preliminary PK data."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_4",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.4.3.2.1",
        "beforeText": "Not explicitly provided in snippet",
        "afterText": "As of 1 November 2017, a total of 37 subjects were enrolled and 36 subjects had completed study treatment.",
        "summary": "Updated enrollment and completion status for Study GS-US-402-3885."
      }
    ],
    "summary": {
      "impactCount": 3,
      "reasonCount": 2,
      "changeCount": 3
    }
  }
}